New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders.

Abstract

Advances in flow cytometry techniques and the availability of monoclonal antibodies that detect key functional molecules on lymphocytes have contributed greatly to a more precise diagnosis of the chronic lymphoproliferative disorders. In addition to the diagnostic value, the expression of certain markers such as p53 or CD38 provides relevant prognostic information to the clinician. Beyond their diagnostic and prognostic value, immunological markers play a major role in the detection of minimal residual disease, enabling the clinician to estimate more accurately the response to chemotherapy. Those monoclonal antibodies that are relevant to the characterisation of the chronic lymphoproliferative disorders and that could be incorporated in a routine practice are discussed.

• Authors: E Matutes
• Journal: Journal of clinical pathology (J Clin Pathol) Vol. 55 Issue 3 Pg. 180-3 (Mar 2002) ISSN: 0021-9746 [Print] England
• PMID: 11896067 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antigens, CD
• Antigens, Differentiation
• Antigens, Neoplasm
• Biomarkers, Tumor
• CD79 Antigens
• CD79B protein, human
• Membrane Glycoproteins
• Neoplasm Proteins
• Tumor Suppressor Protein p53
• Cyclin D1
• ADP-ribosyl Cyclase
• CD38 protein, human
• NAD+ Nucleosidase
• ADP-ribosyl Cyclase 1

Topics

• ADP-ribosyl Cyclase
• ADP-ribosyl Cyclase 1
• Antibodies, Monoclonal (immunology)
• Antigens, CD (immunology)
• Antigens, Differentiation (immunology)
• Antigens, Neoplasm (analysis, immunology)
• Biomarkers, Tumor (analysis, immunology)
• CD79 Antigens
• Chronic Disease
• Cyclin D1 (immunology)
• Humans
• Lymphoproliferative Disorders (diagnosis, immunology)
• Membrane Glycoproteins
• NAD+ Nucleosidase (immunology)
• Neoplasm Proteins (analysis, immunology)
• Tumor Suppressor Protein p53 (immunology)